SCHEMBL1723477

SCHEMBL1723477

[CH2]CCC(C)Cl

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2535452 0.80
SCHEMBL2534473 0.78
SCHEMBL1248824 0.76
SCHEMBL398828 0.76
SCHEMBL2533559 0.76
SCHEMBL246936 0.72
SCHEMBL7217395 0.69 ALDH1A1 (0.39)
SCHEMBL221838 0.69
SCHEMBL2701 0.69
SCHEMBL831616 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 196 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3743061-A1 CANNABINOIDS AND DERIVATIVES FOR PROMOTING IMMUNOGENICITY OF TUMOR AND INFECTED CELLS Pascal Biosciences Inc. (CA) 2020-12-02 EP claimed
WO-2019144126-A1 CANNABINOIDS AND DERIVATIVES FOR PROMOTING IMMUNOGENICITY OF TUMOR AND INFECTED CELLS PASCAL BIOSCIENCES INC. (CA) 2019-07-25 WO claimed
CN-103910738-A Bisbenzylisoquinoline quaternary ammonium salt as well as preparation method and application thereof in preparing antitumor drug UNIV SHANDONG NORMAL 2014-07-09 CN claimed
US-20130122050-A1 COMPOSITIONS AND METHODS FOR TREATING DIABETES USING LISOFYLLINE ANALOGS AND ISLET NEOGENESIS ASSOCIATED PEPTIDE DIAKINE THERAPEUTICS, INC. (US) 2013-05-16 US claimed
US-20110052625-A1 COMPOSITIONS AND METHODS FOR TREATING DIABETES USING LISOFYLLINE ANALOGS AND ISLET NEOGENESIS ASSOCIATED PEPTIDE DIAKINE THERAPEUTICS, INC. (US) 2011-03-03 US claimed
EP-1924558-B1 AN ANTIMALARIAL BAYLIS-HILLMAN ADDUCTS AND A PROCESS FOR THE PREPARATION THEREOF COUNCIL SCIENT IND RES (IN) 2010-01-13 EP claimed
US-20090269313-A1 ENCAPSULATION SYSTEM DIAKINE THERAPEUTICS, INC. (US) 2009-10-29 US claimed
WO-2009099582-A2 COMPOSITIONS AND METHODS FOR TREATING DIABETES USING LISOFYLLINE ANALOGS AND ISLET NEOGENESIS ASSOCIATED PEPTIDE DIAKINE THERAPEUTICS, INC. (US) 2009-08-13 WO claimed
US-20080300189-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RESTORING BETA-CELL MASS AND FUNCTION DIAKINE THERAPEUTICS, INC. (US) 2008-12-04 US claimed
EP-1924558-A1 AN ANTIMALARIAL BAYLIS-HILLMAN ADDUCTS AND A PROCESS FOR THE PREPARATION THEREOF COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2008-05-28 EP claimed
WO-2000061583-A1 XANTHINE DERIVATIVES AND ANALOGS AS CELL SIGNALING INHIBITORS CELL THERAPEUTICS, INC. (US) 2000-10-19 WO claimed
US-6133274-A TREATING DISEASE MEDIATED BY INTRACELLULAR SIGNALING THROUGH ONE OR TWO SPECIFIC INTRACELLULAR SIGNALING PATHWAYS; A XANTHINYL HAVING AT LEAST ONE NITROGEN SUBSTITUTED BY AN HYDROXYALKYL; ANTITUMOR,-CARCINOGENIC,-ARTHRITIC AGENTS CELL THERAPEUTICS, INC. (US) 2000-10-17 US claimed
US-6103730-A Amine substituted compounds CELL THERAPEUTICS, INC. (US) 2000-08-15 US claimed
US-5807861-A Amine substituted xanthinyl compounds CELL THERAPEUTICS, INC. (US) 1998-09-15 US claimed
US-5804584-A USEFUL IN TREATING INDIVIDUALS HAVING A DISEASE OR TREATMENT-INDUCED TOXICITY, MEDIATED BY SECOND MESSENGER ACTIVITY CELL THERAPEUTICS, INC. (US) 1998-09-08 US claimed
US-5801182-A Amine substituted compounds CELL THERAPEUTICS, INC. (US) 1998-09-01 US claimed
US-5780476-A ADMINISTERING TO TREAT INFLAMMATORY DISEASE AND RHEUMATOID ARTHITIS CELL THERAPEUTICS, INC. (US) 1998-07-14 US claimed
EP-0714302-A4 THERAPEUTIC COMPOUNDS CELL THERAPEUTICS INC (US) 1996-10-09 EP claimed
EP-0714302-A1 THERAPEUTIC COMPOUNDS CELL THERAPEUTICS, INC. (US) 1996-06-05 EP claimed
WO-1994022449-A1 THERAPEUTIC COMPOUNDS CELL THERAPEUTICS, INC. (US) 1994-10-13 WO claimed